KEGG   DRUG: Cetrelimab
Entry
D11488                      Drug                                   
Name
Cetrelimab (USAN/INN);
Cetrelimab (genetical recombination) (JAN)
Formula
C6436H9954N1710O2026S42
Exact mass
144957.6709
Mol weight
145046.95
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG IIPIFDTANY
AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARPG LAAAYDTGSL DYWGQGTLVT
VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
QEGNVFSCSV MHEALHNHYT QKSLSLSLGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASQSVR SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RNYWPLTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H1347-L214, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'214, H'150-H'206, H'264-H'324, H'370-H'428, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Antineoplastic, Anti-PD-1 antibody
  Type
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11488  Cetrelimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D11488  Cetrelimab (USAN/INN)
Other DBs
CAS: 2050478-92-5
PubChem: 384585464
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system